Observational research on sodium glucose co‐transporter‐2 inhibitors: A real breakthrough?

Sodium glucose co‐transporter‐2 inhibitors have attracted the interest of the scientific community following the results from dedicated cardiovascular outcome trials, which demonstrated remarkable reduction in all‐cause mortality and other cardiovascular (CV) endpoints with empagliflozin and canagli...

Descripción completa

Detalles Bibliográficos
Autores principales: Raschi, Emanuel, Poluzzi, Elisabetta, Fadini, Gian Paolo, Marchesini, Giulio, De Ponti, Fabrizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6283243/
https://www.ncbi.nlm.nih.gov/pubmed/30003655
http://dx.doi.org/10.1111/dom.13468

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6283243/
https://www.ncbi.nlm.nih.gov/pubmed/30003655
http://dx.doi.org/10.1111/dom.13468

Ejemplares similares